Exploring the influence of steric, electronic and lipophilic descriptors of 1,3-diaryl propenones on their anti-inflammatory activity

*Bhatia N.M., ^2Mahadik K.R., ^1Bhatia M.S.

^1Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur; ^2Department of Pharmaceutical Chemistry BVU Poona College of Pharmacy, Pune, India.

Received 12 Aug 2009; Revised 28 July 2010; Accepted 10 Aug 2010

ABSTRACT

Background and the purpose of the study: Various compounds from natural and synthetic origins containing the 1,3-diarylpropenone structure have been reported to produce a variety of biological activities like anti-microbial, anti-inflammatory, vascular muscle relaxant, etc. A systematic analysis of the structural features responsible for anti-inflammatory activity and a possible mode of their actions were proposed to be evaluated by synthesizing a set of compounds, screening them for anti-inflammatory activity and developing a QSAR model.

Methods: Two types of 1,3-diarylpropenone derivatives were synthesized employing the Claisen-Schmidt condensation. These compounds were then screened for their in vivo anti-inflammatory activity by the carrageenin induced rat paw edema method and also for in vitro cyclooxygenase-2 (COX-2) inhibition activity using a colorimetric kit for COX (ovine) inhibitor screening assay. These derivatives and their anti-inflammatory activity data were employed for QSAR analysis on Vlife MDS 3.5 software. The molecules were divided into training and test sets based on observed activity and QSAR models were generated for the training set and validated. The activity of the molecules of the test set was predicted according to the QSAR equation fit. Possible correlation between observed anti-inflammatory activity and in vitro cyclooxygenase-2 inhibition was also studied.

Results and conclusion: Insignificant difference between the observed and predicted biological activity revealed that the selected electronic, steric and lipophilic parameters have a significant correlation \((r^2 = 0.85)\) with anti-inflammatory activity of the selected class of compounds. On the basis of results it may be suggested that the 1,3-diaryl-2-propen-1-ones framework is an attractive template for structural optimization to achieve better potency of anti-inflammatory activity. Similarly, the relatively low correlation between anti-inflammatory activity and cyclooxygenase-2 inhibition indicates that other modes of actions may also be responsible for the anti-inflammatory activity of the tested compounds.

Keywords: Diarylpropenone; Anti-inflammatory; COX-2; QSAR.

INTRODUCTION

It is well-documented that non-steroidal anti-inflammatory drugs (NSAIDs) exert their effects through inhibition of prostaglandin (PG) synthesis, by blocking cyclooxygenase (COX) activity (1). Two isoforms of the COX enzyme, COX-1 and COX-2, with their functional roles in the maintenance of normal homeostasis and induction of inflammation at inflammatory sites, respectively, were identified early in the past decade (2, 3). Extensive efforts have been made to establish a correlation between structural parameters and biological activity on diverse series of compounds using three-dimensional quantitative structure-activity relationship (3D-QSAR) studies (4).
Anti-inflammatory activity

**In vivo anti-inflammatory activity**

The anti-inflammatory activity was evaluated against carrageenin induced paw edema in albino rats of either sex weighing 150-250g each (20-21). Prior to experiments 0.05ml of freshly prepared suspension of carrageenin (1.0%) in 0.9% saline was injected. One group of six rats was kept as control and other groups were pre-treated with the test and standard drugs at doses plethysmographically of 100 mg/kg orally. Rat paw volume was measured before and 3 hrs after treatment with carrageenin. Increase in volume of paw in each group was measured and percentage of anti-inflammatory activity was calculated by formula:

$$\text{Percentage anti-inflammatory activity} = \left(1 - \frac{V_t}{V_c}\right) \times 100$$

Where $V_t$ and $V_c$ are the volume of paw in edema in drug treated and control group respectively. The ED$_{80}$ values calculated from the data generated are shown in table 2, where ED$_{80}$ is the concentration of the drug to produce 80% response in the animal (21,22).

**In vitro testing [Colorimetric COX (ovine) Inhibitor Screening Assay Kit]**

One hundred and sixty microliters of the assay buffer and 10 µl of heme were added to the background wells. Similarly 150 µl of the assay buffer, 10 µl of heme and 10 µl of enzyme (COX-2) was added to each of the 3 (100% Initial Activity Wells) wells as well as to 3 (Inhibitory Activity Wells) wells. Then 10 µl of inhibitor was added to the inhibitory activity wells while 10 µl of the solvent in which the inhibitors were dissolved was added to each of the 100% initial activity and background wells. These plate were carefully shaken for a few seconds and incubated for 5 minutes at 25°C and then 20 µl of the colorimetric substrate solution was added to all wells. Then 20 µl of arachidonic acid was added to all wells and the plates were shaken carefully for a few seconds and incubated at 25°C for 5 min. The absorbance was measured at 590 nm using plate reader. The absorbance and the calculated IC$_{80}$ values are shown in table 3 where IC$_{80}$ is the concentration of drug required to inhibit 80% of the enzyme.

**QSAR Analysis**

**Data Set**

The builder module of the Vlife MDS was used to generate molecular models of a series of chalcone derivatives. These were then energy-minimized using the Merck Molecular Force Field (MMFF). The structures were energy-minimized until the root mean square (rms) gradient reached to the value of 0.001 kcal mol$^{-1}$ A$^{\circ}$. The charge equilibration method was used to assign atomic partial charges to each of the compounds. pED80 values that is the negative

---

**EXPERIMENTAL**

Twenty four 1,3-diarylprop-2-en-1-ones derivatives (Figure. 1) were synthesized by Claisen-Schmidt condensation (18,19) and evaluated for their anti-inflammatory activity. Among them, chalcones XIII-XVIII are new compounds. The purity of the compound was confirmed by TLC using, silica gel G as stationary phase and ethyl acetate: chloroform (1:2) as mobile phase. The IR spectra were recorded on Jasco FT/IR 4100 spectrophotometer. $^1$H NMR spectra were recorded on Varian NMR 400 MHz spectrometer using DMSO as a solvent and TMS as internal standard. The mass spectra of the compounds were obtained on Micro Mass Q-Top, YA-105. The substituent are shown in table 1.

**Procedure for synthesis of 1,3-diarylprop-2-en-1-ones (I-XXVI)**

To a stirring solution of aldehyde (0.01 mol) in ethanol at room temperature was added 10 ml of 10% sodium hydroxide. To this mixture was added 0.01 mol of the corresponding ketone dropwise with constant stirring. The stirring was continued until final product was precipitated. The product was filtered, washed with water and recrystallized from ethanol to give the respective 1,3-diarylprop-2-en-1-ones. The NMR data of synthesized 1,3-disubstituted prop-2-enones are shown in table 1.

---

![Figure 1. Synthesis of 1,3-diarylprop-2-en-1-ones.](image-url)
Table 1. Ar and Ar′ substituents and NMR data of the propenones I - XXIV.

| Comp. No. | Ar                  | Ar′                  | **NMR (DMSO) δ** |
|-----------|---------------------|---------------------|-----------------|
| I         | 4-methoxyphenyl     | 4-chlorophenyl      | 7.65-7.80 (m, 8H, aromatic) 7.50 (d, 1H, CH=CH, J=15.7 Hz), 7.53 (d, 1H, CH=CH, J=15.7 Hz), 3.84 (s, 3H, OCH3) |
| II        | 4-chlorophenyl      | 4-chlorophenyl      | 7.21-7.79 (m, 8H, aromatic) 7.49 (d, 1H, CH=CH, J=15.6 Hz), 7.22 (d, 1H, CH=CH, J=15.6 Hz) |
| III       | 4-methyl phenyl     | 4-chlorophenyl      | 7.00-7.92 (m, 8H, aromatic) 7.61 (d, 1H, CH=CH, J=15.7 Hz), 7.09 (d, 1H, CH=CH, J=15.7 Hz), 2.38 (s, 3H, CH3) |
| IV        | 4-nitro phenyl      | 4-chlorophenyl      | 7.31-7.92 (m, 8H, aromatic) 7.48 (d, 1H, CH=CH, J=15.5 Hz), 7.30 (d, 1H, CH=CH, J=15.5 Hz) |
| V         | 4-nitro phenyl      | 4-chlorophenyl      | 7.34-7.76 (m, 8H, aromatic) 7.62 (d, 1H, CH=CH, J=15.7 Hz), 7.29 (d, 1H, CH=CH, J=15.7 Hz) |
| VI        | NN-dimethyl-4-aminophenyl | 4-chlorophenyl | 7.49-8.10 (m, 8H, aromatic) 7.52 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 Hz), 2.24 (s, 6H, (N(CH3))2) |
| VII       | 3,4,5-trimethoxyphenyl | 4-chlorophenyl | 7.35-7.71 (m, 6H, aromatic) 7.42 (d, 1H, CH=CH, J=15.6 Hz), 7.14 (d, 1H, CH=CH, J=15.6 Hz), 3.88 (s, 12H, OCH3) |
| VIII      | 4-chlorophenyl      | 3,4,5-trimethoxyphenyl | 7.18-7.79 (m, 6H, aromatic) 7.58 (d, 1H, CH=CH, J=15.7 Hz), 7.21 (d, 1H, CH=CH, J=15.7 Hz), 3.84 (s, 9H, OCH3) |
| IX        | 4-methyl phenyl     | 3,4,5-trimethoxyphenyl | 7.00-7.92 (m, 6H, aromatic) 7.51 (d, 1H, CH=CH, J=15.5 Hz), 7.09 (d, 1H, CH=CH, J=15.5 Hz), 3.84 (s, 9H, OCH3), 2.34 (s, 3H, CH3) |
| X         | 4-bromo phenyl      | 3,4,5-trimethoxyphenyl | 7.11-7.52 (m, 6H, aromatic) 7.58 (d, 1H, CH=CH, J=15.7 Hz), 7.29 (d, 1H, CH=CH, J=15.7 Hz), 3.88 (s, 9H, OCH3) |
| XI        | 4-nitro phenyl      | 3,4,5-trimethoxyphenyl | 7.14-7.46 (m, 6H, aromatic) 7.60 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 Hz), 3.72 (s, 9H, OCH3) |
| XII       | NN-dimethyl-4-aminophenyl | 3,4,5-trimethoxyphenyl | 7.39-7.70 (m, 6H, aromatic) 7.68 (d, 1H, CH=CH), 7.26 (d, 1H, CH=CH), 3.80 (s, 9H, OCH3), 2.31 (s, 6H, (N(CH3))2) |
| XIII      | 4-methoxyphenyl     | Indol-3-yl          | 7.45-8.12 (m, 8H, aromatic) 7.38 (s, 1H, NH), 6.71 (s, 1H, 2-indole), 7.68 (d, 1H, CH=CH), 7.22 (d, 1H, CH=CH), 3.84 (s, 3H, OCH3) and J(Vinylc H) = 15.6 Hz. |
| XIV       | 4-chlorophenyl      | Indol-3-yl          | 7.51-7.79 (m, 8H, aromatic) 7.41 (s, 1H, NH), 6.71 (s, 1H, 2-indole), 7.62 (d, 1H, CH=CH, J=15.7 Hz), 7.27 (d, 1H, CH=CH, J=15.7 Hz) |
| XV        | 4-methyl phenyl     | Indol-3-yl          | 7.40-7.92 (m, 8H, aromatic) 7.34 (s, 1H, NH), 6.61 (s, 1H, 2-indole), 7.57 (d, 1H, CH=CH, J=15.6 Hz), 7.29 (d, 1H, CH=CH, J=15.6 Hz), 2.29 (s, 3H, CH3) |
| XVI       | 4-bromo phenyl      | Indol-3-yl          | 7.45-7.88 (m, 8H, aromatic) 7.39 (s, 1H, NH), 6.71 (s, 1H, 2-indole), 7.61 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 Hz) |
| XVII      | 4-nitro phenyl      | Indol-3-yl          | 7.51-7.91 (m, 8H, aromatic) 7.42 (s, 1H, NH), 6.77 (s, 1H, 2-indole), 7.54 (d, 1H, CH=CH, J=15.9 Hz), 7.14 (d, 1H, CH=CH, J=15.9 Hz) |
| XVIII     | N,N-dimethyl-4aminophenyl | Indol-3-yl          | 7.49-8.10 (m, 8H, aromatic) 7.34 (s, 1H, NH), 6.66 (s, 1H, 2-indole), 7.50 (d, 1H, CH=CH, J=15.5 Hz), 7.20 (d, 1H, CH=CH, J=15.5 Hz), 2.29 (s, 6H, (N(CH3))2) |
| XIX       | 4-methoxyphenyl     | N,N-dimethyl-4aminophenyl | 7.45-7.70 (m, 8H, aromatic) 7.58 (d, 1H, CH=CH, J=15.5 Hz), 7.21 (d, 1H, CH=CH, J=15.5 Hz), 3.82 (s, 3H, OCH3), 2.27 (s, 6H, (N(CH3))2) |
| XX        | 4-chlorophenyl      | N,N-dimethyl-4aminophenyl | 7.61-7.99 (m, 8H, aromatic) 7.62 (d, 1H, CH=CH, J=15.6 Hz), 7.28 (d, 1H, CH=CH, J=15.6 Hz), 2.31 (s, 6H, (N(CH3))2) |
| XXI       | 4-methyl phenyl     | N,N-dimethyl-4aminophenyl | 7.20-7.72 (m, 8H, aromatic) 7.46 (d, 1H, CH=CH, J=15.5 Hz), 7.19 (d, 1H, CH=CH, J=15.5 Hz), 2.33 (s, 3H, CH3), 2.34 (s, 6H, (N(CH3))2) |
| XXII      | 4-bromo phenyl      | N,N-dimethyl-4aminophenyl | 7.42-7.89 (m, 8H, aromatic) 7.59 (d, 1H, CH=CH, J=15.7 Hz), 7.29 (d, 1H, CH=CH, J=15.7 Hz), 2.24 (s, 6H, (N(CH3))2) |
| XXIII     | 4-nitro phenyl      | N,N-dimethyl-4aminophenyl | 7.27-7.86 (m, 8H, aromatic) 7.54 (d, 1H, CH=CH, J=15.8 Hz), 7.22 (d, 1H, CH=CH, J=15.8 Hz), 2.22 (s, 6H, (N(CH3))2) |
| XXIV      | N,N-dimethyl-4aminophenyl | N,N-dimethyl-4aminophenyl | 7.46-8.05 (m, 8H, aromatic) 7.57 (d, 1H, CH=CH, J=15.5 Hz), 7.30 (d, 1H, CH=CH, J=15.5 Hz), 2.24 (s, 9H, 2(N(CH3))2) |
logarithms to the base 10 of the IC₈₀ values, for each compound were used for the present QSAR study. The physicochemical properties of each compound were specified using various descriptors, which delineate lipophilic, conformational, electronic, spatial, structural, thermodynamic and quantum mechanical information. The selected descriptors included the X-component of dipole moment (XD), valence molecular connectivity index (chiV3) and log of partition coefficient calculated as per a atomic contribution model (SLogP). Based on appropriate representation of quantitative sub-classes of biological activity, from the 24 compounds 18 were randomly chosen for the training set and the remaining compounds were used as test set for checking the external predictivity of generated QSAR models. The selected model developed by using the training set was used to predict the activity of the compounds in the test set and subsequently to predict the activity of all 24 compounds by leaving a group out every time.

Table 2. Anti-inflammatory activity of synthesized compounds I - XXIV.

| Comp. No | % Reduction in Edema (±SD)* | pED80 |
|----------|------------------------------|-------|
| I        | 46.11 (±1.49)               | -0.04844 |
| II       | 97.24 (±0.92)               | 0.2757 |
| III      | 89.22 (±1.06)               | 0.2382 |
| IV       | 94.60 (±0.74)               | 0.2636 |
| V        | 78.44 (±0.67)               | 0.1823 |
| VI       | 34.05 (±0.84)               | -0.1801 |
| VII      | 60.20 (±2.16)               | 0.0673 |
| VIII     | 88.44 (±0.97)               | 0.2344 |
| IX       | 26.65 (±0.47)               | -0.2865 |
| X        | 85.32 (±1.46)               | 0.2188 |
| XI       | 33.06 (±0.84)               | -0.1928 |
| XII      | 16.54 (±1.24)               | -0.4937 |
| XIII     | 56.89 (±0.92)               | 0.0427 |
| XIV      | 97.08 (±1.40)               | 0.2749 |
| XV       | 75.94 (±1.12)               | 0.1682 |
| XVI      | 93.09 (±0.53)               | 0.2566 |
| XVII     | 83.24 (±0.45)               | 0.2081 |
| XVIII    | 52.92 (±0.96)               | 0.0113 |
| XIX      | 69.88 (±1.07)               | 0.1321 |
| XX       | 62.15 (±0.81)               | 0.0811 |
| XXI      | 42.18 (±0.58)               | -0.0870 |
| XXII     | 60.58 (±1.30)               | 0.07007 |
| XXIII    | 27.62 (±1.35)               | -0.2710 |
| XXIV     | 12.82 (±1.04)               | -0.6043 |
| Ibuprofen| 88.09 (±0.86)               | |

Table 3. Percentage (%) of COX-2 inhibitory activity of the synthesized compounds I - XXIV.

| Compd. no. | Conc. µg/ml | Average Absorbance (600 nm) |
|------------|-------------|-----------------------------|
| Background Well | -           | 0.248                       |
| 100% Initial Activity Well | -           | 0.420                       |
| I          | 10          | 0.272                       |
| II         | 10          | 0.367                       |
| III        | 10          | 0.359                       |
| IV         | 10          | 0.312                       |
| V          | 10          | 0.328                       |
| VI         | 10          | 0.258                       |
| VII        | 10          | 0.306                       |
| VIII       | 10          | 0.366                       |
| IX         | 10          | 0.266                       |
| X          | 10          | 0.351                       |
| XI         | 10          | 0.260                       |
| XII        | 10          | 0.297                       |
| XIII       | 10          | 0.317                       |
| XIV        | 10          | 0.398                       |
| XV         | 10          | 0.316                       |
| XVI        | 10          | 0.305                       |
| XVII       | 10          | 0.358                       |
| XVIII      | 10          | 0.330                       |
| XIX        | 10          | 0.335                       |
| XX         | 10          | 0.324                       |
| XXI        | 10          | 0.297                       |
| XXII       | 10          | 0.317                       |
| XXIII      | 10          | 0.275                       |
| XXIV       | 10          | 0.262                       |

Full Search Multiple Linear Regression Method

A relationship between independent and dependent variables (physicochemical descriptors and biological activities, respectively) were determined statistically using regression analysis. Linear regression was achieved by fitting a best-fit straight line to the data using the least squares method. Descriptors that are included in a reasonable QSAR equation should exhibit high correlation to biological activity and low inter-correlation so that a diverse set of independent variables with high correlation to activity are selected. High correlation with targeted activity followed by low inter-correlation between descriptors were the criteria which were used for selection of descriptors for equation and the quality of fit for a regression equation was assessed relative to its correlation coefficient and standard deviation. The F value represents the level of statistical significance of the regression. Quality of selected models was further ascertained to select the best model from cross-validated squared correlation coefficient (q²). In
The relation for \( q^2 \) shown below,

\[
q^2 = 1 - \text{PRESS/TOTAL}
\]

\( \Sigma(Y_{\text{predicted}} - Y_{\text{observed}})^2 \) is the predictive error sum of squares (PRESS). \( \Sigma(Y_{\text{observed}} - Y_{\text{mean}})^2 \) is the total sum of squares (TOTAL), where \( Y_{\text{predicted}} \) and \( Y_{\text{observed}} \) are the predicted, observed, and mean values of activity, respectively. For a regression model, \( r^2 \) was used to describe the fitness of data and fitness is considered to improve as \( r^2 \) approaches 1. Thus models having correlation coefficient above 0.7 were used to check the external predictivity while the significance of the model was decided on the basis of F value. Models showing \( q^2 \) below 0.6 were discarded. The selected model fulfilling above criteria is given in table 4 and correlation matrix of the descriptors in the selected model is given is table 5.

### Activity prediction

To assess a QSAR model systematically, a reliable validation is required. Usually, a QSAR model is evaluated by the predictive results for the given data-set. Selected models having \( r^2 \) above 0.7 were checked for their external predictivity. The observed and the predicted values for anti-inflammatory activity are shown in table 6.

### RESULTS AND DISCUSSION

In the present work some 1,3-diarylpropenone derivatives were synthesized by nucleophilic condensation of aldehyde and ketones as per reported procedure. The purity and structure products were confirmed by chromatographic and spectral data analysis. The IR absorption bands in the range from 1540-1559 and 1655-1686 cm\(^{-1}\) indicated the presence of a conjugated carbonyl group (C=C-C=O) and confirmed the formation of the propenone derivatives. The \(^1\)H NMR spectrum of these compounds shows the presence of two doublets of vinylic protons at \( \delta \) 7.09 to 7.68 (\( J = \) 15.5 to 15.9 Hz) indicating presence of only the E-isomers of all compounds including the Ar`, Indol-3-yl substituent.

The compounds were screened for anti-inflammatory activity by carrageenin induced rat paw edema method, using ibuprofen as standard. The COX-2 inhibitory activity was also checked and a comparative account of both activities for the 24 synthesized compounds is presented graphically in figure 2. The correlation coefficient for in vitro COX-2 inhibition versus the in vivo anti-inflammatory activity is 0.61. This value is an indication that COX-2 inhibition may not be the sole mechanism by which these compounds act as anti-inflammatory agents and other mechanisms like inhibition of the lipoxynase and heme oxygenase-1 by the active compounds should also be studied.

Similarly, amongst the compounds showing good anti-inflammatory activity, the low residuals of

### Table 4. QSAR model generated for the in vivo anti-inflammatory activity.

| QSAR model                      | N | \( r^2 \) | \( q^2 \) | F value | Pred \( r^2 \) | SE  |
|---------------------------------|---|----------|---------|---------|--------------|-----|
| pED80 = 0.3952 SlogP - 0.0214 chIV3 - 0.053 XD - 1.0123 | 19 | 0.794 | 0.657 | 31.00 | 0.718 | 0.105 |

### Table 5. Correlation matrix of descriptors used in the study.

| Slog P | chIV3 | XD  |
|--------|-------|-----|
| Slog P | 1.000000 | 0.036276 | 0.214725 |
| chIV3  | 0.036276 | 1.000000 | 0.090551 |
| XD     | 0.214725 | 0.090551 | 1.000000 |

* All the values are calculated on the Vlife sciences MDS 3.5.

### Table 6. Observed in vivo anti-inflammatory activity, predicted activity and residuals.

| Comp. No. | Observed pED80 | Predicted pED80* | Residuals* |
|-----------|----------------|------------------|------------|
| I         | -0.048         | -0.076           | 0.028      |
| II        | 0.275          | 0.251            | 0.025      |
| III       | 0.238          | 0.223            | 0.015      |
| IV        | 0.263          | 0.301            | -0.037     |
| V         | 0.182          | 0.112            | 0.070      |
| VI        | -0.180         | -0.020           | -0.160     |
| VII       | 0.067          | -0.023           | 0.090      |
| VIII      | 0.234          | 0.096            | 0.138      |
| IX        | -0.286         | -0.067           | -0.219     |
| X         | 0.218          | 0.153            | 0.066      |
| XI        | -0.192         | -0.079           | -0.114     |
| XII       | -0.493         | -0.358           | -0.135     |
| XIII      | 0.042          | 0.095            | -0.052     |
| XIV       | 0.274          | 0.267            | 0.008      |
| XV        | 0.168          | 0.088            | 0.080      |
| XVI       | 0.256          | 0.349            | -0.092     |
| XVII      | 0.208          | 0.173            | 0.035      |
| XVIII     | 0.011          | -0.146           | 0.157      |
| XIX       | 0.132          | -0.160           | 0.292      |
| XX        | 0.081          | 0.064            | 0.017      |
| XXI       | -0.087         | -0.249           | 0.162      |
| XXII      | 0.070          | 0.100            | -0.030     |
| XXIII     | -0.271         | -0.206           | -0.065     |
| XXIV      | -0.604         | -0.460           | -0.144     |

* Calculated by Vlife MDS 3.5

* All the values are calculated on the Vlife sciences MDS 3.5.
Compound numbers II, III, IV and XIV indicate good predictability of the QSAR model for these compounds while in the case of the remaining active compounds, V, VIII, X, XVI and XVII, the predicted activity deviates highly from the observed activity. These results also indicate that the selected set of descriptors have relevance to a certain target receptor whereas some other modes of action involving different receptors may have a significant contribution in the observed anti-inflammatory action of the compounds whose predicted activities show large deviations from their observed activities. The selected QSAR model was found best to express anti-inflammatory activity as confirmed by validation of the model judging internal and external predictivity and other statistical terms like the predicted $r^2$, $F$ value and $q^2$. The variable terms in the equation together yield a good correlation to the targeted activity showing low correlation among themselves and hence show a diverse set of variables influencing biological activity. As indicated in table 5 the anti-inflammatory activity increases by increase in SlogP and decreases in chiV3 and XD within the limits explored for this work. As it is evident from the compounds producing better activity, an electronegative atom like chlorine or bromine are distant from the electron rich pyrrolo of the indolyl substituent and structural features enhancing the dipole are likely to improve activity. Similarly the increase in the multiplicity of substituents could positively contribute to chiV3 and hence compounds with multiple substituents like methoxy and dimethylamino are less active. Atomic contributions to partition coefficient which would increase hydrophilicity and polarity and hence decrease in the partition coefficient within the range covered by the compounds of this work could possibly improve anti-inflammatory activity. The presence of a 4-bromophenyl and indolyl substituents in compound XIV resulted in good anti-inflammatory activity but the COX-2 inhibition was relatively low.

CONCLUSION

QSAR analysis on a structurally diverse but small set of propenones has led to the identification of structural, electronic and steric factors contributing to anti-inflammatory activity and COX-2 selectivity. Robust statistical parameters handled the physicochemical descriptors effectively to rule out chance co-relations with an acceptable level of approximations. Evaluation and comparison of the QSAR analysis with the results of COX-2 selectivity and potency led to understanding that though, COX-2 inhibition may possibly be the mechanism for the anti-inflammatory action but it does not solely account for the anti-inflammatory activity shown by all the synthesized propenone derivatives. The correlation of the exhibited activity is required to be explored with other targets for anti-inflammatory compounds like heme oxygenase-1, lipoxygenase, etc. Moreover, the awareness and understanding of the descriptors influencing both the affinity and selectivity properties of these compounds could provide an opportunity to understand and optimize appropriate features of the ligand structures which correlate with the biological data. As a consequence, the outcome of this study could be useful as a guide for further development of safer COX-2 inhibitors and anti-inflammatory drugs.

ACKNOWLEDGEMENT

The authors are thankful to Dr. H. N. More, Principal, Bharati Vidyapeeth College of Pharmacy, Kolhapur for providing facilities to carry out the research work.

REFERENCES

1. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biology, 1971; 231: 232-235.
2. Marnett L.J, Kalgotkar A.S Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future. Trends Pharm. Sci., 1999; 20: 465-469.
3. Allison M.C, Howatson A.G, Torrance C.J, Lee F.D, Russel R.I. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. New Engl. J. Med., 1992; 327: 749-754.
4. Zambre A.P, Ganure A.L, Shinde D.B, Kulkarni V.M. Perspective assessment of COX-1 and COX-2 Selectivity of Nonsteroidal Anti-Inflammatory Drugs from Clinical Practice: Use of Genetic Function Approximation. J. Chem. Inf. Model., 2007; 47: 635-643.
5. Fatima A.O, Adel A.E. Synthesis of polyfunctionally substituted heteroaromatic compounds via
benzotriazolyl chalcones with antimicrobial and antifungal activities. J. Heterocycl. Chem., 2004; 41: 327-333.
6. Khan M.S.Y, Hasan S.M. Synthesis, antiinflammatory and antibacterial activity of some new flavonoidal derivatives. Indian J. Chem., 2003; 42B: 1970-1974.
7. Lahitchev K.L, Batovska D.I, Parusheev S.P, Ubiylov V.M, Sibirny A.A. Antifungal activity of chalcones: a mechanistic study using various yeast strains. Eur. J. Med. Chem., 2008; 43: 2220-2228.
8. Sivakumar P.M, Seenivasan P.S, Kumar V, Doble M. Synthesis, antinococcal activity evaluation and QSAR studies of chalcone derivatives. Bioorg. Med. Chem. Lett., 2007; 17: 1695-1700.
9. Solanke A, Patel J. Synthesis of chalcones, pyrazolines, aminopyrimidines and pyrimidinethiones as antibacterial agents. Indian J. Chem., 2004; 43B: 1580-1584.
10. Liu M, Wilairat P, Croft S.L, Tan A.L, Go M.L. Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg. Med. Chem., 2003; 11: 2729-2738.
11. Xu Y.C, Leung S.W.S, Yeung D.K.Y, Hu L.H, Chen GH, Che C.M, Man R.Y.K. Structure-activity relationships of flavonoids for vascular relaxation in porcine coronary artery. Phytochem., 2007; 68: 1179-1188.
12. Herencia F, Lopez-Garcia M.P, Ubeda A, Ferrandiz, M.L. Nitric oxide-scavenging properties of some chalcone derivatives. Nitric Oxide, 2002; 6: 242-246.
13. Hasan A, Khan K.M, Sher M, Maharvi G.M, Nawaz S.A, Choudhary M.I, Atta-Ur-Rahman, Supuran CT. Synthesis and inhibitory potential towards acetylcholinesterase, butrylcholinesterase and lipoxygenase of some variably substituted chalcones J. Enz. Inh. Med. Chem., 2005; 20: 41-47.
14. Hsieh H.K, Lee T.H, Wang J.P, Wang JJ, Lin C.N. Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res., 1998; 15: 39-46.
15. Herencia F, Ferrandiz, M.L, Ubeda A, Dominguez J.N, Charris J.E, Lobo G.M, Alcaraz M.J. Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorg. Med. Chem. Lett., 1998; 8: 1169-1174.
16. De Leon E.J, Alcaraz M.J, Terencio M.C, Dominguez J.N, Charris J. A new chloroquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats. J. Pharm. Pharmacol., 2003; 55: 1313-1321.
17. Ostad S.N, Motahhary P, Beshkar M, Ghahremani M.H. 17β-estradiol and progesterone upregulate cyclooxygenase-2 expression in the human gingival fibroblasts. DARU, 2006; 14: 190-196. Foresti R, Hoque M, Monti D, Green C.J, Motterlini R. J. Differential activation of heme oxygenase-1 by chalcones and rosolic acid in endothelial cells. Pharmacol. Exp. Ther., 2005; 312: 686-693.
18. Furniss B.S, Hannaford A.J, Smith P.W.G, Tatchell A.R. Vogel’s textbook of practical organic chemistry, New York, ELBS publications. 1988; 5th edn., 1034-1035.
19. Gasull E.I, Silber JJ, Blanco S.E, Tomas F, Ferretti F.H. A theoretical and experimental study of the formation mechanism of 4-X-chalcones by the Claisen-Schmidt reaction. THEOCHEM, 2000; 503: 131-144.
20. Ratheesh M, Helen A. Anti-inflammatory activity of Ruta graveolens Linn on carrageenan induced paw edema in wistar male rats. Afr. J. Biotechnol., 2007; 6: 1209-1211.
21. Vogel G.H, Drug discovery and evaluation: Pharmacological assays, Springer-Verlag Berlin Heidelberg, New York, 2002; 2nd edn., 725-771.
22. Teorell T. Kinetics of distribution of substances administered to the body. I: The extravascular modes of administration. Arch. Int. Pharmacodynam., 1937; 57: 205-225.